Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds HC Wainwright & Co. Downgrades TCR2 Therapeutics to Neutral

HC Wainwright & Co. Downgrades TCR2 Therapeutics to Neutral

HC Wainwright & Co. analyst Robert Burns downgrades TCR2 Therapeutics (NASDAQ:TCRR) from Buy to Neutral.

byBenzinga Newsdesk

March 7, 2023

1 minute read

HC Wainwright & Co. analyst Robert Burns downgrades TCR2 Therapeutics (NASDAQ:TCRR) from Buy to Neutral.

Analyst Ratings

A Glimpse Into The Expert Outlook On Delta Air Lines Through 9 Analysts

By Benzinga Insights

May 13, 8:00 AM

Analysts’ ratings for Delta Air Lines (NYSE:DAL) over the last quarter vary from bullish to bearish, as provided…

DAL

Why Is Liver Disease Focused Tharimmune Stock Trading Higher Today?

By Vandana Singh

November 27, 11:01 AM

Tharimmune Inc (NASDAQ: THAR) released phase 1 data with TH104, a proprietary

THAR

ARC Document Solutions Q3 EPS $0.09 Beats $0.07 Estimate, Sales $73.14M Beat $71.00M Estimate

By Benzinga Newsdesk

November 2, 4:07 PM

ARC Document Solutions (NYSE:ARC) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $0.07 by 28.57 percent. This is a 12.5 percent increase over earnings of $0.08 per share from

ARC

Why CEL-SCI (CVM) Shares Are Down 20%

By Henry Khederian

July 18, 11:07 AM

CEL-SCI Corporation (NASDAQ: CVM) shares are trading lower by 21.3% to $2.25 Tuesday morning after the company priced its public offering of 2.5 million shares at $2.00 per share.

CVM

HC Wainwright & Co. Downgrades TCR2 Therapeutics to Neutral

Related Posts

A Glimpse Into The Expert Outlook On Delta Air Lines Through 9 Analysts

Why Is Liver Disease Focused Tharimmune Stock Trading Higher Today?

ARC Document Solutions Q3 EPS $0.09 Beats $0.07 Estimate, Sales $73.14M Beat $71.00M Estimate

Why CEL-SCI (CVM) Shares Are Down 20%